Kommentar zu: Adagrasib bei KRAS-G12C-mutierten kolorektalen Karzinomen effektiv

• Literatur

• 1 Yaeger R, Weiss J, Pelster MS. et al. Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRASG12C. N Engl J Med 2023; 388: 44-54
• 2 Fakih MG, Kopetz S, Kuboki Y. et al. Sotorasib for previously treated colorectal cancers with KRASG12C mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trial. Lancet Oncol 2022; 23: 115-124
• 3 Kuboki Y, Yaeger R, Fakih MG. et al. Sotorasib in combination with panitumumab in refractory KRAS G12C-mutated colorectal cancer: Safety and efficacy for phase Ib full expansion cohort. Ann Oncol 2022; 33 (Suppl. 7) S136-S196
• 4 Sacher A, LoRusso P, Patel MR. et al. Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation. N Engl J Med 2023; 389: 710-721
• 5 Awad MM, Liu S, Rybkin II. et al. Acquired Resistance to KRASG12C Inhibition in Cancer. N Engl J Med 2021; 384: 2382-2393